<DOC>
	<DOCNO>NCT01379703</DOCNO>
	<brief_summary>KaleEAST non-interventional , post-marketing observational study ( PMOS ) lopinavir/ritonavir prescribe usual manner accordance term local marketing authorization regard dose , population indication . No additional procedure ( standard care ) apply patient . The KaleEAST PMOS conduct prospective , single-arm , multicountry , multicenter format . The study carry two ( 2 ) part : first part initiate 2004 lopinavir/ritonavir capsule formulation , second part start 2006 lopinavir/ritonavir tablet become available participating country . The aim post-marketing observational study obtain data clinical , biological , virological outcome , compliance tolerability Kaletra®-containing regimen routine clinical use participate country .</brief_summary>
	<brief_title>Multicountry , Multicenter Post-Marketing Observational Study Clinical , Biological Virological Outcomes , Compliance Tolerability Kaletra® Routine Clinical Use</brief_title>
	<detailed_description>As study observational nature , subject follow-up specify protocol leave judgment physician within 18 month period , defines survey participant . For indicative purpose , follow-up participant enable approximately 7 visit period . These visit take place average interval 3 month , apart first visit follow inclusion ( usually end first treatment month ) apart visit require intercurrent event . Participant visit assign follow : Baseline/Day 0 ( start lopinavir/ritonavir treatment ) , Month 1 ( day 1 day 45 ) , Month 3 ( day 46 day 136 ) , Month 6 ( day 137 day 228 ) , Month 9 ( day 229 day 319 ) , Month 12 ( day 320 day 410 ) , Month 15 ( day 411 day 501 ) , Month 18 ( day 502 day 593 ) . Each participant plan observe his/her lopinavir/ritonavir capsule contain treatment regimen maximum period 18 month , participant plan observe his/her lopinavir/ritonavir tablet contain treatment regimen maximum period 9 month .</detailed_description>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Patients infect HIV1 infection either : Antiretroviral treatment ( ART ) naive Had fail intolerant one previous combine antiretroviral treatment ( cART ) , include Protease inhibitor ( PI ) ( firstline pretreated without Protease inhibitor ) Had fail intolerant one previous antiretroviral treatment ART , include one Protease inhibitor ( firstline pretreated Protease Inhibitor ) . A ritonavirboosted Protease inhibitor PI consider treatment one Protease inhibitor PI . Treatment drug risk interaction lopinavir/ritonavir Uncontrolled AIDS define disease Two previous Protease inhibitor ( PIs ) Participation another study clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>HIV-1 infect patient</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Kaletra®</keyword>
</DOC>